PRGO - Perrigo Company PLC
Executive Summary
Perrigo Company plc is an Irish-domiciled consumer self-care company listed on the NYSE under the ticker PRGO, headquartered in Dublin and founded in 1887. It manufactures and sells over-the-counter (OTC) medicines, vitamins, nutritional supplements, infant formula and dermatology products, with a heavy weighting toward private-label and store-brand lines sold through major retailers in North America and Europe. The company holds a leading position in US store-brand OTC analgesics and infant formula, supplying retailer own-label products that sit adjacent to branded competitors such as Haleon and Kenvue.
The investment case rests on continued execution of the Three-S plan, balance-sheet repair through divestiture proceeds, and a credible H2 2026 operating improvement. The most concrete near-term milestone is the Q2 2026 earnings release, expected on the standard early-August cadence following the Q1 2026 print on 6 May 2026, which will provide the first read on whether the maintained full-year guidance and the Dermacosmetics divestiture proceeds are translating into margin recovery. The principal risk is that intensified competition from larger branded and consumer-health players, disclosed in SEC risk factors, continues to compress volumes and pricing power across OTC and infant formula categories.
OPPORTUNISTIC BUY. Conviction Score: 62/100. The view would be upgraded on a clean Q2 print with raised guidance or visible net-debt reduction ahead of plan, and would be downgraded on further category share losses, a renewed regulatory setback, or a deterioration in the competitive backdrop that prevents the H2 2026 margin recovery from materialising.
Business Model
Perrigo generates revenue primarily through the manufacture and sale of consumer self-care products to retailers, wholesalers and distributors, with the bulk of sales routed through private-label and store-brand programmes. The operating segments cover Consumer Self-Care Americas, Consumer Self-Care International (focused on European OTC brands and the Voltaren topical pain franchise sold in collaboration with Haleon in certain markets), and a smaller specialty and nutrition footprint that historically included the now-divested Dermacosmetics business. Geographic mix is heavily skewed to North America, with Europe contributing the remainder.
Customers are principally large grocery, drugstore, mass-merchant and club-channel retailers that purchase Perrigo-manufactured products under their own labels, alongside branded sales through the same retail partners. Private-label OTC, store-brand infant formula and store-brand dermatology represent the highest-volume lines, while the branded portfolio (including topical pain and digestive health products) provides incremental margin and shelf positioning. The model is volume-led and manufacturing-cost-sensitive, so gross margin is heavily influenced by raw material costs, plant utilisation and product mix between high-volume private label and higher-margin branded SKUs.
The competitive moat, where one exists, rests on Perrigo's scale as a low-cost manufacturer of regulated OTC and nutritional products, its FDA-inspected manufacturing footprint, and its long-standing retailer relationships in private label. These advantages are genuine but narrowing: SEC filings disclose that larger and better-capitalised competitors, specifically Haleon and Kenvue, are increasing competitive intensity in the same categories, which limits pricing power and the pace of share gains. The recent Dermacosmetics divestiture sharpens focus on the core OTC and self-care platform but reduces earnings diversification.
Financial Snapshot
Recent Catalysts
[6 August 2025] - Perrigo reported second quarter 2025 financial results from continuing operations and, in commentary from then-President and CEO Patrick Lockwood-Taylor, framed the previously announced sale of the Dermacosmetics business as a step toward simplifying the portfolio. Source: Perrigo investor relations (press release dated 2025-08-06).
[22 April 2026] - Perrigo confirmed it would release first quarter 2026 financial results on 6 May 2026, restating its positioning as a leading provider of consumer self-care products and setting the date for the next earnings update. Source: Perrigo investor relations press release dated 22 April 2026.
[6 May 2026] - Perrigo reported first quarter 2026 financial results from continuing operations, with the company describing the print as a beat versus consensus and reaffirming full-year 2026 guidance. Source: Perrigo press release via PR Newswire dated 6 May 2026.
[7 May 2026] - Coverage noted Perrigo's release of its FY 2026 earnings guidance alongside the quarterly print, confirming the maintained outlook first disclosed with the Q1 results. Source: Daily Political coverage dated 7 May 2026.
[Q2 2026 reporting window] - Perrigo has not yet announced a specific Q2 2026 release date in the research provided; based on the historical early-August cadence and the Q2 2025 print dated 6 August 2025, investors should expect the next quarterly update in early August 2026. Source: Perrigo investor relations cadence inferred from prior release pattern (2025-08-06 and 2026-05-06 prints).
Thesis Evaluation
Bull Case (29% weight)
Perrigo sustains organic revenue growth in the mid-single digits, lifts gross margin by 150-200 basis points over H2 2026 as the Three-S plan delivers, and applies Dermacosmetics divestiture proceeds to net debt alongside further non-core divestments. Competitive pressure from Haleon and Kenvue remains a manageable headwind rather than an accelerating one, and 2027 guidance is raised on the back of a clean OTC and infant formula cadence. A 12-month price target of 16.00 implies meaningful upside from the current USD10.11, with re-rating contingent on visible margin expansion.
Base Case (50% weight)
The Three-S plan grinds forward with modest organic growth, modest gross margin recovery of 50-100 basis points across 2026, and a steady reduction in net debt using divestiture proceeds. Guidance is maintained but not raised, the Q2 print lands close to consensus, and category share trends are roughly flat against larger branded competitors. The 12-month outcome is a slow re-rating back toward the lower end of the historical band, with a price target of 12.50.
Bear Case (21% weight)
Competitive intensity from Haleon, Kenvue and private-label rivals accelerates, infant formula volumes weaken further, and pricing power in OTC erodes, capping gross margin recovery despite cost actions. Guidance is cut during 2026, net-debt reduction stalls, and the market re-prices Perrigo for a structural earnings downgrade. The 12-month downside target is 7.50, below the current USD10.11 and approaching the 52-week low of USD9.23.
Key Risks
- Intensifying competition from larger branded and consumer-health peers: SEC-disclosed risk factors highlight ongoing category pressure from larger players such as Haleon and Kenvue, which could cap Perrigo's market-share gains and compress OTC and infant formula margins. Estimated probability: 65%. Impact: severe.
- Failure of the Three-S operational restructuring plan: If the Three-S plan fails to deliver the targeted cost savings and gross margin uplift, the H2 2026 improvement thesis does not materialise and earnings remain depressed. Estimated probability: 35%. Impact: severe.
- Infant formula category volatility and prior regulatory exposure: Perrigo's infant formula business was previously constrained by an FDA warning letter at the Allegan facility (resolved in 2025), and any renewed regulatory action or category disruption would directly hit a high-volume franchise. Estimated probability: 20%. Impact: severe.
- Balance sheet and refinancing risk on net debt: With a market capitalisation of around USD1.4bn against ongoing net debt, slower-than-expected proceeds from divestitures or weaker free cash flow would pressure the deleveraging path. Estimated probability: 30%. Impact: moderate.
- FX and European OTC exposure: Approximately a quarter of revenue is generated in Europe, so sterling and euro weakness against the US dollar would translate reported revenue and margin lower. Estimated probability: 40%. Impact: low.
- Loss of key retailer private-label contracts: A significant portion of revenue is concentrated in private-label programmes with large US and European retailers; the loss or non-renewal of a major contract would create an immediate volume gap that is difficult to replace. Estimated probability: 15%. Impact: severe.
Who Should Own It / Avoid It
Ideal for: patient, valuation-driven investors with a higher tolerance for execution risk and a minimum 18-24 month holding horizon who are comfortable owning a turnaround-style consumer healthcare name trading near multi-year lows. The position should be sized as a small-to-mid weight within a diversified healthcare or value sleeve, with the expectation that returns depend on operational execution rather than multiple expansion alone.
Avoid if: investors require stable, predictable earnings growth, cannot tolerate a continued share-price drawdown to the USD9 area, or are unwilling to underwrite a multi-quarter restructuring story in a competitive consumer-health market. Short-horizon traders, income-focused holders seeking reliable dividend growth, and investors with strict loss-tolerance thresholds should look elsewhere.
Recommendation
OPPORTUNISTIC BUY - 62/100. The rating reflects a balance between tangible progress on controllable levers (the Dermacosmetics divestiture, Q1 2026 beat and maintained guidance) and persistent competitive and category risks that justify only an opportunistic, valuation-anchored stance rather than a high-conviction core holding. The call would be upgraded toward a standard Buy on a Q2 2026 print that shows clean margin expansion, further non-core divestitures, or a step-change in net-debt reduction. It would be downgraded toward Hold or Reduce on a guidance cut, renewed regulatory action at a key facility, or evidence that Haleon or Kenvue are taking durable share in core OTC categories. At the current price of $10.11 the shares trade above our buy ceiling of $9.17: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is $12.47, 23% above the current price of $10.11 - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $9.17 - below this level the upside to the base-case target ($12.50) is at least 2x the downside to the bear case ($7.50), the minimum risk/reward we require before committing new capital.
between $9.17 and $12.50 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $12.50 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 29%.
if A material cut to full-year 2026 guidance, a renewed FDA warning letter at a Perrigo manufacturing facility, or a major loss of a US private-label retailer contract that visibly impairs the deleveraging and margin recovery path, regardless of price - the bear target of $7.50 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 62/100. Trend versus prior report: Down.
| Report date | Conviction |
|---|---|
| 2026-08-01 | 29 |
| 2026-07-25 | 53 |
| 2026-06-28 | 61 |
| 2026-05-30 | 52 |
| 2026-04-27 | 62 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Company press releases, investor relations announcements, earnings disclosures, regulatory filings referenced through public news flow, and third-party financial news commentary covering the Q1 2026 print, FY 2026 guidance, and the Dermacosmetics divestiture.
Primary source types: SEC filings (including risk-factor disclosures referenced for competitive context), Perrigo Company plc press releases and investor relations materials, PR Newswire earnings releases, and earnings call disclosures for Q2 2025 and Q1 2026.
Key sources
- Perrigo (PRGO) Earnings Date and Reports 2026
- Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
- Perrigo (PRGO) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026
- Perrigo (PRGO) Stock Forecast & Price Target
- Media Releases | corporate
- Who are the main competitors of Perrigo?
- PRGO 2024 Annual Report
- Quality, Affordable Self-Care Products[sup]TM[/sup] | corporate
Data correct as of 2026-08-01.